In the latest trading session, 2.32 million Medtronic Plc (NYSE:MDT) shares changed hands as the company’s beta touched 0.80. With the company’s most recent per share price at $91.56 changed hands at -$0.65 or -0.71% at last look, the market valuation stands at $117.43B. MDT’s current price is a discount, trading about -5.12% off its 52-week high of $96.25. The share price had its 52-week low at $75.96, which suggests the last value was 17.04% up since then. When we look at Medtronic Plc’s average trading volume, we note the 10-day average is 7.84 million shares, with the 3-month average coming to 7.29 million.
Analysts gave the Medtronic Plc (MDT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.39. If we narrow down to specifics, the data shows that 1 out of 15 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 7 recommended MDT as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Medtronic Plc’s EPS for the current quarter is expected to be 1.58.
Medtronic Plc (NYSE:MDT) trade information
Instantly MDT was in red as seen in intraday trades today. With action 0.05%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 14.62%, with the 5-day performance at 0.05% in the green. However, in the 30-day time frame, Medtronic Plc (NYSE:MDT) is 6.38% up. Looking at the short shares, we see there were 13.49 million shares sold at short interest cover period of 1.94 days.
The consensus price target for the stock as assigned by Wall Street analysts is 96, meaning bulls need an upside of 4.62% from its recent market value. According to analyst projections, MDT’s forecast low is 92 with 105 as the target high. To hit the forecast high, the stock’s price needs a -14.68% plunge from its current level, while the stock would need to soar -0.48% for it to hit the projected low.
Medtronic Plc (MDT) estimates and forecasts
Year-over-year growth is forecast to reach 3.51% up from the last financial year.
Consensus estimates given by 26 financial analysts project the company’s revenue in the current quarter to hit an average of 8.81B. 17 analysts are of the opinion that Medtronic Plc’s revenue for the current quarter will be 8.32B. The company’s revenue for the corresponding quarters a year ago was 8.59B and 7.92B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 2.57%. The estimates for the next quarter sales put growth at 5.08%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.12%. The 2025 estimates are for Medtronic Plc earnings to increase by 4.88%, but the outlook for the next 5-year period is at 6.57% per year.
MDT Dividends
Medtronic Plc is expected to release its next quarterly earnings report on 2025-Feb-17. The 3.05% annual yield figure for the share gives it an annual dividend of 2.79. It is important to note, however, that the 3.05% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 2.74 per year.
Medtronic Plc (NYSE:MDT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.26% of Medtronic Plc shares while 86.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 86.40%. There are 86.18% institutions holding the Medtronic Plc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.5358% of the shares, roughly 126.61 million MDT shares worth $9.97 billion.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.4275% or 111.89 million shares worth $8.81 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. With 40.17 shares estimated at $3.67 billion under it, the former controlled 3.13% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.71% of the shares, roughly 34.72 shares worth around $3.17 billion.
